Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Mak LY"" wg kryterium: Autor


Tytuł:
Anti-HBc: a significant host predictor of spontaneous HBsAg seroclearance in chronic hepatitis B patients - a retrospective longitudinal study.
Autorzy:
Kan K; Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong, China.; State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, China.
Wong DK; Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong, China.; State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, China.
Hui RW; Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong, China.
Seto WK; Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong, China.; State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, China.
Yuen MF; Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong, China. .; State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, China. .
Mak LY; Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong, China. .; State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, China. .
Pokaż więcej
Źródło:
BMC gastroenterology [BMC Gastroenterol] 2023 Oct 06; Vol. 23 (1), pp. 348. Date of Electronic Publication: 2023 Oct 06.
Typ publikacji:
Journal Article
MeSH Terms:
Hepatitis B Surface Antigens*
Hepatitis B, Chronic*/drug therapy
Humans ; Male ; Middle Aged ; Aged ; Female ; Retrospective Studies ; Longitudinal Studies ; Hepatitis B Antibodies/therapeutic use ; Hepatitis B virus/genetics ; DNA, Viral ; Hepatitis B e Antigens
Czasopismo naukowe
Tytuł:
Hepatitis B virus reactivation in seronegative occult hepatitis B patient receiving ibrutinib therapy.
Autorzy:
Lam LK; Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Pokfulam, Hongkong.
Chan TSY; Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Pokfulam, Hongkong.
Hwang YY; Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Pokfulam, Hongkong.
Mak LY; Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Pokfulam, Hongkong.; State Key Laboratory of Liver Research, The University of Hong Kong, Pokfulam, Hongkong.
Seto WK; Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Pokfulam, Hongkong.; State Key Laboratory of Liver Research, The University of Hong Kong, Pokfulam, Hongkong.
Kwong YL; Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Pokfulam, Hongkong.
Yuen MF; Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Pokfulam, Hongkong. .; State Key Laboratory of Liver Research, The University of Hong Kong, Pokfulam, Hongkong. .; Queen Mary Hospital, Professorial Block, 102, Pokfulam Road, Hong Kong. .
Pokaż więcej
Źródło:
Virology journal [Virol J] 2023 Aug 01; Vol. 20 (1), pp. 168. Date of Electronic Publication: 2023 Aug 01.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Hepatitis B virus*/genetics
Hepatitis B*/complications
Hepatitis B*/drug therapy
Humans ; Female ; Aged, 80 and over ; Hepatitis B Surface Antigens ; Hepatitis B Antibodies ; Antiviral Agents/adverse effects ; Virus Activation ; DNA, Viral
Czasopismo naukowe
Tytuł:
Long-term Hepatitis B Surface Antigen Profile and Seroclearance after Severe Acute Flares of Chronic Hepatitis B.
Autorzy:
Hui KY; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR, China.
Fung J; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR, China.
Cheung KS; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR, China.; Department of Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
Mak LY; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR, China.; State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong SAR, China.
Seto WK; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR, China.; Department of Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.; State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong SAR, China.
Yuen MF; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR, China.; State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong SAR, China.
Pokaż więcej
Źródło:
Gut and liver [Gut Liver] 2023 Mar 15; Vol. 17 (2), pp. 280-287. Date of Electronic Publication: 2022 Nov 01.
Typ publikacji:
Journal Article
MeSH Terms:
Hepatitis B Surface Antigens*/blood
Hepatitis B, Chronic*/blood
Hepatitis B, Chronic*/complications
Hepatitis B, Chronic*/immunology
Humans ; Alanine Transaminase ; Carcinoma, Hepatocellular ; Hepatitis B virus/immunology ; Liver Neoplasms
Czasopismo naukowe
Tytuł:
Remdesivir use and risks of acute kidney injury and acute liver injury among patients hospitalised with COVID-19: a self-controlled case series study.
Autorzy:
Wong CKH; Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.; Department of Family Medicine and Primary Care, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.; Laboratory of Data Discovery for Health Limited (D24H), Hong Kong Science Park, Hong Kong SAR, China.
Au ICH; Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Cheng WY; School of Biomedical Sciences, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Man KKC; Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.; Research Department of Practice and Policy, UCL School of Pharmacy, London, UK.
Lau KTK; Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Mak LY; Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.; State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong SAR, China.
Lui SL; Department of Medicine, Tung Wah Hospital, Hong Kong SAR, China.
Chung MSH; Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Xiong X; Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Lau EHY; Laboratory of Data Discovery for Health Limited (D24H), Hong Kong Science Park, Hong Kong SAR, China.; WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, SAR, China.
Cowling BJ; Laboratory of Data Discovery for Health Limited (D24H), Hong Kong Science Park, Hong Kong SAR, China.; WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, SAR, China.
Pokaż więcej
Źródło:
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2022 Jul; Vol. 56 (1), pp. 121-130. Date of Electronic Publication: 2022 Mar 22.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Acute Kidney Injury*/chemically induced
Acute Kidney Injury*/epidemiology
COVID-19 Drug Treatment*
Adenosine Monophosphate/analogs & derivatives ; Alanine/analogs & derivatives ; Hong Kong ; Humans ; Liver ; Retrospective Studies ; Risk Factors ; SARS-CoV-2
Czasopismo naukowe
Tytuł:
Editorial: liver and kidney injury from remdesivir-an issue not as much as its purpose. Authors' reply.
Autorzy:
Wong CKH; Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.; Department of Family Medicine and Primary Care, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.; Laboratory of Data Discovery for Health Limited (D24H), Hong Kong Science Park, Hong Kong SAR, China.
Au ICH; Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Cheng WY; School of Biomedical Sciences, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Man KKC; Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.; Research Department of Practice and Policy, UCL School of Pharmacy, London, UK.
Lau KTK; Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Mak LY; Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.; State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong SAR, China.
Lui SL; Department of Medicine, Tung Wah Hospital, Hong Kong SAR, China.
Chung MSH; Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Xiong X; Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Lau EHY; Laboratory of Data Discovery for Health Limited (D24H), Hong Kong Science Park, Hong Kong SAR, China.; WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, Hong Kong SAR, China.
Cowling BJ; Laboratory of Data Discovery for Health Limited (D24H), Hong Kong Science Park, Hong Kong SAR, China.; WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, LKS Faculty of Medicine, Hong Kong SAR, China.
Pokaż więcej
Źródło:
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2022 Jun; Vol. 55 (11), pp. 1457-1458.
Typ publikacji:
Editorial; Research Support, Non-U.S. Gov't; Comment
MeSH Terms:
Alanine*/adverse effects
Alanine*/analogs & derivatives
Liver*
Adenosine Monophosphate/adverse effects ; Adenosine Monophosphate/analogs & derivatives ; Humans ; Kidney
Raport
Tytuł:
Early Treatment Consideration in Patients with Hepatitis B 'e' Antigen-Positive Chronic Infection: Is It Time for a Paradigm Shift?
Autorzy:
Koffas A; Barts Liver Centre, Centre for Immunobiology, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, UK.
Mak LY; Barts Liver Centre, Centre for Immunobiology, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, UK.; Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong.
Gill US; Barts Liver Centre, Centre for Immunobiology, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, UK.
Kennedy PTF; Barts Liver Centre, Centre for Immunobiology, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, UK.
Pokaż więcej
Źródło:
Viruses [Viruses] 2022 Apr 26; Vol. 14 (5). Date of Electronic Publication: 2022 Apr 26.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Carcinoma, Hepatocellular*/drug therapy
Carcinoma, Hepatocellular*/etiology
Hepatitis B, Chronic*/complications
Hepatitis B, Chronic*/drug therapy
Liver Neoplasms*/drug therapy
Liver Neoplasms*/etiology
Adult ; Antiviral Agents/therapeutic use ; Hepatitis B e Antigens ; Humans ; Liver Cirrhosis/etiology ; Persistent Infection
Czasopismo naukowe
Tytuł:
On-treatment gamma-glutamyl transferase predicts the development of hepatocellular carcinoma in chronic hepatitis B patients.
Autorzy:
Huang CF; Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.; Faculty of Internal Medicine and Hepatitis Research Center, College of Medicine, and Center for Cohort Study, Kaohsiung Medical University, Kaohsiung, Taiwan.
Jang TY; Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.; Department of Internal Medicine, Pingtung Hospital, Ministry of Health and Welfare, Ping-Tung, Taiwan.
Jun DW; Department of Internal Medicine, Hanyang University Hospital, Hanyang University College of Medicine, Seoul, South Korea.
Ahn SB; Department of Internal Medicine, Nowon Eulji Medical Center, Eulji University College of Medicine, Seoul, South Korea.
An J; Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, South Korea.
Enomoto M; Department of Hepatology, Osaka City University Graduate School of Medicine, Osaka, Japan.
Takahashi H; Liver Center, Saga University Hospital, Saga, Japan.; Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University, Saga, Japan.; Locomedical General Institute, Locomedical Eguchi Hospital, Saga, Japan.
Ogawa E; Department of General Internal Medicine, Kyushu University, Fukuoka, Japan.
Yoon E; Department of Internal Medicine, Hanyang University Hospital, Hanyang University College of Medicine, Seoul, South Korea.
Jeong SW; Department of Internal Medicine, Soonchunhyang University Hospital, Soonchunhyang University College of Medicine, Seoul, South Korea.
Shim JJ; Department of Internal Medicine, Kyung Hee University Hospital, Kyung Hee University School of Medicine, Seoul, South Korea.
Jeong JY; Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, South Korea.; Department of Internal Medicine, National Medical Center, Seoul, South Korea.
Kim SE; Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyan, South Korea.
Oh H; Department of Internal Medicine, Uijeongbu Eulji Medical Center, Eulji University School of Medicine, Uijeongbu, South Korea.
Kim HS; Department of Internal Medicine, Hallym University Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, South Korea.
Cho YK; Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Kozuka R; Department of Hepatology, Osaka City University Graduate School of Medicine, Osaka, Japan.
Inoue K; Liver Center, Saga University Hospital, Saga, Japan.; Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University, Saga, Japan.; Locomedical General Institute, Locomedical Eguchi Hospital, Saga, Japan.
Cheung KS; Department of Medicine, The University of Hong Kong, Hong Kong, Hong Kong.; State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, Hong Kong.
Mak LY; Department of Medicine, The University of Hong Kong, Hong Kong, Hong Kong.; State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, Hong Kong.
Huang JF; Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.; Faculty of Internal Medicine and Hepatitis Research Center, College of Medicine, and Center for Cohort Study, Kaohsiung Medical University, Kaohsiung, Taiwan.
Dai CY; Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.; Faculty of Internal Medicine and Hepatitis Research Center, College of Medicine, and Center for Cohort Study, Kaohsiung Medical University, Kaohsiung, Taiwan.
Yuen MF; Department of Medicine, The University of Hong Kong, Hong Kong, Hong Kong.; State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, Hong Kong.
Nguyen MH; Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University Medical Center, Palo Alto, California, USA.
Yu ML; Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.; Faculty of Internal Medicine and Hepatitis Research Center, College of Medicine, and Center for Cohort Study, Kaohsiung Medical University, Kaohsiung, Taiwan.
Pokaż więcej
Źródło:
Liver international : official journal of the International Association for the Study of the Liver [Liver Int] 2022 Jan; Vol. 42 (1), pp. 59-68. Date of Electronic Publication: 2021 Nov 29.
Typ publikacji:
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma, Hepatocellular*
Hepatitis B, Chronic*/complications
Hepatitis B, Chronic*/drug therapy
Liver Neoplasms*/etiology
Aged ; Humans ; Incidence ; Liver Cirrhosis/complications ; Male ; Retrospective Studies ; Risk Factors ; gamma-Glutamyltransferase
Czasopismo naukowe
Tytuł:
Novel Antivirals in Clinical Development for Chronic Hepatitis B Infection.
Autorzy:
Mak LY; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam Road 102, Hong Kong, China.; State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, China.
Seto WK; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam Road 102, Hong Kong, China.; State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, China.
Yuen MF; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam Road 102, Hong Kong, China.; State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, China.
Pokaż więcej
Źródło:
Viruses [Viruses] 2021 Jun 18; Vol. 13 (6). Date of Electronic Publication: 2021 Jun 18.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Antiviral Agents/*pharmacology
Drug Discovery/*methods
Hepatitis B virus/*drug effects
Hepatitis B, Chronic/*drug therapy
Virus Replication/*drug effects
Drug Development/methods ; Host Microbial Interactions/drug effects ; Humans ; Immune Checkpoint Inhibitors/pharmacology ; Immunologic Factors/pharmacology
Czasopismo naukowe
Tytuł:
First-line oral antiviral therapies showed similar efficacies in suppression of serum HBcrAg in chronic hepatitis B patients.
Autorzy:
Mak LY; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam Road 102,, Pok Fu Lam, Hong Kong.; State Key Laboratory of Liver Research, The University of Hong Kong, Pok Fu Lam, Hong Kong.
Wong DK; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam Road 102,, Pok Fu Lam, Hong Kong.; State Key Laboratory of Liver Research, The University of Hong Kong, Pok Fu Lam, Hong Kong.
Cheung KS; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam Road 102,, Pok Fu Lam, Hong Kong.; Department of Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
Seto WK; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam Road 102,, Pok Fu Lam, Hong Kong.; State Key Laboratory of Liver Research, The University of Hong Kong, Pok Fu Lam, Hong Kong.
Fung J; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam Road 102,, Pok Fu Lam, Hong Kong.; State Key Laboratory of Liver Research, The University of Hong Kong, Pok Fu Lam, Hong Kong.
Yuen MF; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam Road 102,, Pok Fu Lam, Hong Kong. .; State Key Laboratory of Liver Research, The University of Hong Kong, Pok Fu Lam, Hong Kong. .
Pokaż więcej
Źródło:
BMC gastroenterology [BMC Gastroenterol] 2021 Mar 17; Vol. 21 (1), pp. 123. Date of Electronic Publication: 2021 Mar 17.
Typ publikacji:
Journal Article
MeSH Terms:
Hepatitis B, Chronic*/drug therapy
Antiviral Agents/therapeutic use ; DNA, Viral ; Hepatitis B Core Antigens ; Hepatitis B e Antigens ; Hepatitis B virus/genetics ; Humans ; Japan ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Entecavir Reduced Serum Hepatitis B Core-Related Antigen in Chronic Hepatitis B Patients with Hepatocellular Carcinoma.
Autorzy:
Mak LY; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, China.
Ko KL; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, China.
To WP; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, China.
Wong DK; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, China.; State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, China.
Seto WK; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, China.; State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, China.; Department of Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
Fung J; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, China.; State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, China.
Yuen MF; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, China.; State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, China.
Pokaż więcej
Źródło:
Gut and liver [Gut Liver] 2020 Sep 15; Vol. 14 (5), pp. 665-668.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/drug therapy
Carcinoma, Hepatocellular*/etiology
Hepatitis B, Chronic*/complications
Hepatitis B, Chronic*/drug therapy
Liver Neoplasms*/drug therapy
Liver Neoplasms*/etiology
Antiviral Agents/therapeutic use ; Biomarkers ; DNA, Viral ; Female ; Guanine/analogs & derivatives ; Hepatitis B Core Antigens ; Hepatitis B e Antigens ; Hepatitis B virus ; Humans ; Male ; Middle Aged ; Treatment Outcome
Czasopismo naukowe
Tytuł:
A large real-world cohort study examining the effects of long-term entecavir on hepatocellular carcinoma and HBsAg seroclearance.
Autorzy:
Ko KL; Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong.
To WP; Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong.
Mak LY; Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong.
Seto WK; Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong.; State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong, Hong Kong.
Ning Q; Institute of Infectious Disease, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.
Fung J; Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong.; State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong, Hong Kong.
Lai CL; Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong.; State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong, Hong Kong.
Yuen MF; Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong.; State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong, Hong Kong.
Pokaż więcej
Źródło:
Journal of viral hepatitis [J Viral Hepat] 2020 Apr; Vol. 27 (4), pp. 397-406. Date of Electronic Publication: 2019 Dec 09.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/prevention & control
Liver Neoplasms*/prevention & control
Antiviral Agents/*therapeutic use
Guanine/*analogs & derivatives
Hepatitis B/*drug therapy
Hepatitis B Surface Antigens/*blood
Cohort Studies ; DNA, Viral ; Guanine/therapeutic use ; Humans
Czasopismo naukowe
Tytuł:
Hepatitis B core-related antigen levels after HBeAg seroconversion is associated with the development of hepatocellular carcinoma.
Autorzy:
To WP; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.
Mak LY; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.
Wong DK; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.; State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong, China.
Fung J; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.; State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong, China.
Liu F; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.
Seto WK; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.; State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong, China.; Department of Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
Lai CL; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.; State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong, China.
Yuen MF; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.; State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong, China.
Pokaż więcej
Źródło:
Journal of viral hepatitis [J Viral Hepat] 2019 Dec; Vol. 26 (12), pp. 1473-1480. Date of Electronic Publication: 2019 Sep 02.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma, Hepatocellular/*blood
Carcinoma, Hepatocellular/*etiology
Hepatitis B Core Antigens/*blood
Hepatitis B e Antigens/*blood
Hepatitis B, Chronic/*complications
Liver Neoplasms/*blood
Liver Neoplasms/*etiology
Adult ; Biomarkers ; Carcinoma, Hepatocellular/diagnosis ; Disease Susceptibility ; Female ; Hepatitis B Core Antigens/immunology ; Hepatitis B e Antigens/immunology ; Hepatitis B virus/immunology ; Hepatitis B, Chronic/immunology ; Hepatitis B, Chronic/virology ; Humans ; Incidence ; Liver Neoplasms/diagnosis ; Male ; Middle Aged ; Proportional Hazards Models ; ROC Curve ; Risk Factors ; Seroconversion
Czasopismo naukowe
Tytuł:
New Biomarkers of Chronic Hepatitis B.
Autorzy:
Mak LY; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong.
Seto WK; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong.; State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong.; Department of Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
Fung J; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong.; State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong.
Yuen MF; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong.; State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong.
Pokaż więcej
Źródło:
Gut and liver [Gut Liver] 2019 Nov 15; Vol. 13 (6), pp. 589-595.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Hepatitis B virus*
Hepatitis B Core Antigens/*blood
Hepatitis B, Chronic/*blood
Hepatitis B, Chronic/*diagnosis
RNA, Viral/*blood
Biomarkers/blood ; Humans
Czasopismo naukowe
Tytuł:
Targeted genomic profiling identifies frequent deleterious mutations in FAT4 and TP53 genes in HBV-associated hepatocellular carcinoma.
Autorzy:
Huang FY; Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong SAR, Hong Kong.
Wong DK; Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong SAR, Hong Kong.; State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong SAR, Hong Kong.
Tsui VW; Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong SAR, Hong Kong.
Seto WK; Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong SAR, Hong Kong.; State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong SAR, Hong Kong.
Mak LY; Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong SAR, Hong Kong.
Cheung TT; State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong SAR, Hong Kong.; Department of Surgery, The University of Hong Kong, Queen Mary Hospital, Hong Kong SAR, Hong Kong.
Lai KK; Depatment of Pathology, City of Hope National Medical Center, Duarte, CA, USA.; Department of Molecular Medicine, Beckman Research Institute of City of Hope, Duarte, CA, USA.; City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Yuen MF; Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong SAR, Hong Kong. .; State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong SAR, Hong Kong. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2019 Aug 08; Vol. 19 (1), pp. 789. Date of Electronic Publication: 2019 Aug 08.
Typ publikacji:
Journal Article
MeSH Terms:
Biomarkers, Tumor*
Mutation*
Cadherins/*genetics
Carcinoma, Hepatocellular/*etiology
Hepatitis B/*complications
Liver Neoplasms/*etiology
Tumor Suppressor Protein p53/*genetics
Tumor Suppressor Proteins/*genetics
Alleles ; Cell Line, Tumor ; DNA Mutational Analysis ; Gene Expression Profiling ; Gene Frequency ; Genomics/methods ; Hepatitis B/virology ; Hepatitis B virus ; Humans ; INDEL Mutation
Czasopismo naukowe
Tytuł:
Fibrosis evolution in chronic hepatitis B e antigen-negative patients across a 10-year interval.
Autorzy:
Mak LY; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.
Seto WK; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.; State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, China.
Hui RW; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.
Fung J; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.; State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, China.
Wong DK; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.; State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, China.
Lai CL; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.; State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, China.
Yuen MF; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.; State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, China.
Pokaż więcej
Źródło:
Journal of viral hepatitis [J Viral Hepat] 2019 Jul; Vol. 26 (7), pp. 818-827. Date of Electronic Publication: 2019 Apr 16.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Hepatitis B e Antigens*/blood
Hepatitis B e Antigens*/immunology
Hepatitis B, Chronic/*complications
Hepatitis B, Chronic/*epidemiology
Liver Cirrhosis/*epidemiology
Liver Cirrhosis/*etiology
Liver Cirrhosis/*pathology
Adult ; Biomarkers ; Disease Progression ; Disease Susceptibility ; Female ; Hepatitis B Surface Antigens/blood ; Hepatitis B, Chronic/blood ; Hepatitis B, Chronic/immunology ; Humans ; Liver Function Tests ; Male ; Middle Aged ; Patient Outcome Assessment ; Public Health Surveillance ; Seroconversion ; Seroepidemiologic Studies ; Severity of Illness Index ; Viral Load
Czasopismo naukowe
Tytuł:
Association of adipokines with hepatic steatosis and fibrosis in chronic hepatitis B patients on long-term nucleoside analogue.
Autorzy:
Mak LY; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.
Lee CH; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.; Research Centre of Heart, Brain, Hormone and Healthy Aging, The University of Hong Kong, Hong Kong, China.
Cheung KS; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.
Wong DK; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.; State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong, China.
Liu F; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.
Hui RW; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.
Fung J; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.; State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong, China.
Xu A; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.; Department of Pharmacology & Pharmacy, The University of Hong Kong, Hong Kong, China.; State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Hong Kong, China.
Lam KS; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.
Yuen MF; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.; State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong, China.
Seto WK; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.; State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong, China.; Department of Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
Pokaż więcej
Źródło:
Liver international : official journal of the International Association for the Study of the Liver [Liver Int] 2019 Jul; Vol. 39 (7), pp. 1217-1225. Date of Electronic Publication: 2019 Apr 11.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Adipokines/*blood
Antiviral Agents/*therapeutic use
Hepatitis B, Chronic/*drug therapy
Liver Cirrhosis/*epidemiology
Non-alcoholic Fatty Liver Disease/*epidemiology
Nucleosides/*analogs & derivatives
Nucleosides/*therapeutic use
Aged ; Body Mass Index ; Cohort Studies ; Disease Progression ; Elasticity Imaging Techniques ; Fatty Acid-Binding Proteins/blood ; Female ; Fibroblast Growth Factors/blood ; Hepatitis B, Chronic/blood ; Hepatitis B, Chronic/complications ; Hong Kong/epidemiology ; Humans ; Liver Cirrhosis/blood ; Liver Cirrhosis/diagnostic imaging ; Logistic Models ; Male ; Middle Aged ; Non-alcoholic Fatty Liver Disease/blood ; Risk Factors
Czasopismo naukowe
Tytuł:
Editorial: can hepatitis B core-related antigen be the new biomarker for hepatocellular carcinoma in nucleoside analogue-treated chronic hepatitis B?
Autorzy:
Mak LY; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong.
Pokaż więcej
Źródło:
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2019 Apr; Vol. 49 (7), pp. 954-955.
Typ publikacji:
Editorial; Comment
MeSH Terms:
Carcinoma, Hepatocellular*
Hepatitis B, Chronic*
Liver Neoplasms*
Biomarkers ; Hepatitis B Core Antigens ; Hepatitis B virus ; Humans ; Incidence ; Nucleosides
Opinia redakcyjna
Tytuł:
Letter: serum HBcrAg is a useful marker for disease monitoring, predicting treatment response and disease outcome of chronic hepatitis B virus infection-authors' reply.
Autorzy:
Mak LY; Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong.
Yuen MF; Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong.; State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong.
Pokaż więcej
Źródło:
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2018 Jun; Vol. 47 (12), pp. 1720-1721.
Typ publikacji:
Letter; Comment
MeSH Terms:
Hepatitis B Core Antigens*
Hepatitis B, Chronic*
Hepatitis B e Antigens ; Hepatitis B virus ; Humans
Opinia redakcyjna
Tytuł:
Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection.
Autorzy:
Mak LY; Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong.
Wong DK; Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong.; State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong, Hong Kong.
Cheung KS; Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong.
Seto WK; Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong.; State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong, Hong Kong.
Lai CL; Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong.; State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong, Hong Kong.
Yuen MF; Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong.; State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong, Hong Kong.
Pokaż więcej
Źródło:
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2018 Jan; Vol. 47 (1), pp. 43-54. Date of Electronic Publication: 2017 Oct 16.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Hepatitis B Core Antigens/*blood
Hepatitis B e Antigens/*blood
Hepatitis B, Chronic/*virology
Biomarkers/blood ; Biopsy ; Carcinoma, Hepatocellular/virology ; DNA, Circular ; DNA, Viral/blood ; Hepatitis B Surface Antigens/blood ; Hepatitis B virus/genetics ; Hepatitis B, Chronic/drug therapy ; Humans ; Liver Neoplasms/virology
Czasopismo naukowe
Tytuł:
The role of interleukin-27 in predicting spontaneous HBeAg seroconversion in chronic hepatitis B infection.
Autorzy:
Li J; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, Hong Kong.; Department of Infectious Disease, Shandong Provincial Hospital Affiliated to Shandong University, Shandong, China.
Mak LY; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, Hong Kong.
Wong DK; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, Hong Kong.; State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong, Hong Kong.
Fung J; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, Hong Kong.; State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong, Hong Kong.
Seto WK; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, Hong Kong.; State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong, Hong Kong.
Lai CL; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, Hong Kong.; State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong, Hong Kong.
Yuen MF; Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, Hong Kong.; State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong, Hong Kong.
Pokaż więcej
Źródło:
Liver international : official journal of the International Association for the Study of the Liver [Liver Int] 2017 Sep; Vol. 37 (9), pp. 1287-1294. Date of Electronic Publication: 2017 Feb 10.
Typ publikacji:
Journal Article
MeSH Terms:
DNA, Viral/*blood
Hepatitis B e Antigens/*blood
Hepatitis B, Chronic/*immunology
Interleukin-27/*blood
Adolescent ; Adult ; Biomarkers/blood ; Female ; Hepatitis B Antibodies/blood ; Hepatitis B virus ; Hepatitis B, Chronic/diagnosis ; Humans ; Liver Function Tests ; Logistic Models ; Male ; Middle Aged ; Multivariate Analysis ; Predictive Value of Tests ; Young Adult
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies